Radius Health, Inc. (NASDAQ:RDUS) insider Jesper Hoiland purchased 6,100 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were bought at an average price of $32.72 per share, with a total value of $199,592.00. Following the purchase, the insider now owns 6,100 shares in the company, valued at $199,592. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Radius Health, Inc. (NASDAQ:RDUS) traded up 1.67% on Friday, reaching $33.54. 2,913,154 shares of the company traded hands. The stock’s market capitalization is $1.46 billion. Radius Health, Inc. has a 1-year low of $31.58 and a 1-year high of $59.22. The stock’s 50-day moving average is $37.54 and its 200-day moving average is $39.19.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million for the quarter, compared to analyst estimates of $1.96 million. During the same period in the prior year, the firm posted ($1.01) EPS. Equities research analysts expect that Radius Health, Inc. will post ($5.58) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Jesper Hoiland Acquires 6,100 Shares of Radius Health, Inc. (RDUS) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/15/jesper-hoiland-acquires-6100-shares-of-radius-health-inc-rdus-stock.html.

A number of hedge funds have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. lifted its position in Radius Health by 1.1% during the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after purchasing an additional 46 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 180 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Radius Health by 19.9% in the second quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock valued at $148,000 after acquiring an additional 541 shares during the period. Sei Investments Co. raised its stake in shares of Radius Health by 27.7% in the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 690 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. raised its stake in shares of Radius Health by 4.1% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 17,605 shares of the biopharmaceutical company’s stock valued at $795,000 after acquiring an additional 690 shares during the period.

RDUS has been the subject of several research analyst reports. Cantor Fitzgerald set a $65.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research note on Monday, May 22nd. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. ValuEngine upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Maxim Group set a $24.00 price target on shares of Radius Health and gave the stock a “sell” rating in a research note on Wednesday, May 24th. Finally, BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. Radius Health has a consensus rating of “Hold” and a consensus price target of $53.60.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Insider Buying and Selling by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.